Skip to search formSkip to main contentSkip to account menu

dansylsarcosine

Known as: dans-sarcosine 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Dansyl CompoundsSarcosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Cross‐linked human serum albumin dimer has the potential for use as a plasma‐retaining agent for the fatty acid‐conjugated antidiabetic drugs
The half‐life of fatty acid‐conjugated antidiabetic drugs are prolonged through binding to albumin, but this may not occur in… 
2011
2011
Effects of nonenzymatic glycation and fatty acids on functional properties of human albumin.
2007
2007
Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor.
Highly Cited
2004
Highly Cited
2004
The interaction of human serum albumin with a novel antidiabetic agent--SU-118.
SU-118 is a newly synthesized antidiabetic agent and shows the best hypoglycemic effect among a series of analogs. Its binding… 
Highly Cited
2001
Highly Cited
2001
Interaction Mechanism Between Indoxyl Sulfate, a Typical Uremic Toxin Bound to Site II, and Ligands Bound to Site I of Human Serum Albumin
AbstractPurpose. The study was performed for clarifying the mechanism of interaction between indoxyl sulfate (IS), a typical… 
1998
1998
Monoacylglycerol binding to human serum albumin: evidence that monooleoylglycerol binds at the dansylsarcosine site.
The binding of monoacylglycerides of long-chain fatty acids to human serum albumin has been examined using monooleoylglycerol as… 
1992
1992
A comparison of drug binding sites on mammalian albumins.
Highly Cited
1991
Highly Cited
1991
Binding inhibitors restore furosemide potency in tubule fluid containing albumin.
We have previously suggested that albumin in tubule fluid at concentrations found in the nephrotic syndrome (NS) binds furosemide… 
1987
1987
A novel binding site for bile acids on human serum albumin.
1978
1978
The fatty acid content and drug binding characteristics of commercial albumin preparations.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)